CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Catalent Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Catalent Inc
14 Schoolhouse Rd
Phone: (732) 537-6200p:732 537-6200 SOMERSET, NJ  08873-1213  United States Ticker: CTLTCTLT
Business Summary
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board John J.Greisch 68 8/28/2023 2/16/2018
President, Chief Executive Officer, Director AlessandroMaselli 51 7/1/2022 10/1/2016
President, Division Head for BioProduct Delivery and Chief of Staff Ricky W.Hopson 48 8/1/2023 7/1/2022
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Hepatic Cell Therapy Support SA RUE AUGUSTE PICCARD 37 CHARLEROI BE
Skeletal Cell Therapy Support SA Rue Auguste Piccard 37 Charleroi Belgium
MaSTherCell Global Inc. 48 Rue Auguste Piccard Gosselies Belgium
11 additional Subsidiary records available in full report.

Business Names
Business Name
12 Catalent CTS (Wales) Limited (UNITED KINGDOM)
14 Catalent Dusseldorf Gmbh (GERMANY)
22 Catalent Gosselies SA (BELGIUM)
137 additional Business Names available in full report.

General Information
Number of Employees: 16,900 (As of 6/30/2024)
Outstanding Shares: 181,511,586 (As of 10/23/2024)
Shareholders: 7
Stock Exchange: NYSE
Federal Tax Id: 208737688
Fax Number: (732) 537-6480


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024